23 November 2022 in BJU International
1 June 2020 in Journal of Pediatric Urology
1 December 2022 in Journal of Urology
Introduction:Tumor markers alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG) and lactate dehydrogenase (LDH) assume a key role in the management of testicular germ cell tumors (GCT). Whil...
9 December 2024 in Canadian Urological Association Journal
Introduction: Robotic-assisted surgery (RAS) is a vital modality in the armamentarium of minimally invasive surgeons. The HugoTM RAS system (Medtronic®) is one of the newest platforms on the market and has little surgical outcomes data. We describe our early experience performing robotic-assisted partial nephrectomy (RAPNx) with the Hugo RAS platform. Methods: We conducted a retrospective review of patients who underwent a RAPNx with the Hugo RAS platform between April and December 2023 at the University Health Network in Toronto, ON. One surgeon performed all procedures using a three-arm transperitoneal approach. Anesthetic, operative, and pathologic reports were assessed to collect pre-, intra- and postoperative variables. Results: Eleven patients were included. The mean age was 51 years, 45.0% were female, and 63.6% had a right-sided mass. Mean tumor size was 2.9 cm. Mean warm ischemia time was 18.9 min (standard deviation [SD] 7.12) and mean estimated blood loss was 179 mL (SD 63.6). Mean robot docking time was 232 seconds (SD 106.5), mean total console time was 93 minutes (SD 21.4), and mean total operative time was 165.6 minutes (SD 34.1). There were no intraoperative complications. On pathology review, most tumors were a clear cell variant (72.7%) and staged pT1a (81.8%). All margins were negative. One patient sustained a port site infection. Conclusions: This is the first North American case series using the Hugo RAS platform for RAPNx. Our findings underscore that the platform is safe and effective for performing RAPNx with comparable outcomes to other robotic platforms.
12 October 2019 in BJU International
In 2015 the Lancet Commission on Global Surgery drew significant attention to the international demand for surgical care and the importance of incorporating surgery into the global health agenda. This initiative added a renewed impetus to the advancement of the discipline of global surgery. To date, urology has operated on the margins of the broader global surgery agenda. This is not surprising given that in resource‐restricted environments, even simple triage of symptoms can overwhelm healthcare providers and other stakeholders. Constraints to safe anesthesia, inadequate surgical equipment and stagnant health systems infrastructure are commonplace. Current global surgery efforts that focus on building capacity for the ‘Bellwether’ procedures (open fracture repair, laparotomy, and caesarean section) as initial priorities seem appropriate, representing areas that can have the greatest impact.
22 May 2020 in Journal of the American Geriatrics Society